SEGMENT INFORMATION

6 Months Ended

Jun. 30, 2016

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, and royalties from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our revenues are currently derived primarily from the sale of Altrazeal® in sixteen international markets and from our sales activities in the United States.  With respect to revenues for the three and six months ended June 30, 2016, revenues reported for international sales represent the recognition of previously unamortized licensing fees only and do not include any Altrazeal® product sales.

Revenues per geographic area for the three and six months ended June 30 are summarized as follows:

	Three Months Ended June 30,										Six months Ended June 30,
Revenues	2016		%			2015		%			2016		%			2015		%
Domestic	$	4,520		2	%	$	7,085		3	%	$	12,036		3	%	$	13,887		3	%
International		259,813		98	%		251,912		97	%		361,089		97	%		539,758		97	%
Total	$	264,333		100	%	$	258,997		100	%	$	373,125		100	%	$	553,645		100	%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total sales, along with their relative percentage of all sales, for the three and six months ended June 30 are represented on the following table:

		Three Months Ended June 30,						Six months Ended June 30,
Customers	Product	2016			2015			2016			2015
Customer A	Altrazeal®		---			91	%		---			92	%
Customer B	Altrazeal®		88	%		2	%		64	%		2	%
Customer C	Altrazeal®		---			1	%		25	%		1	%
Total			88	%		94	%		89	%		95	%